Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 13/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | WHR1 | P49842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16184575 | 0.94 | GBA1 (0.43) | GBA1LMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL16184603 | 0.94 | CCNT1 (0.44) | GBA1LMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL16184634 | 0.94 | CCNT1 (0.44) | GBA1LMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL16184547 | 0.91 | GBA1 (0.45) | GBA1LMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL16184660 | 0.91 | GBA1 (0.45) | GBA1LMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL14474226 | 0.91 | GBA1 (0.43) | GBA1LMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL16184522 | 0.90 | GBA1 (0.44) | GBA1LMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL16184484 | 0.87 | GBA1 (0.54) | GBA1LMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL16184481 | 0.84 | GBA1 (0.56) | GBA1 | |
| SCHEMBL16184496 | 0.83 | CYP1A2 (0.44) | LMNAMAPTSMN1; SMN2DYRK1ACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | GBA1 1316/4885LMNA 4832/4885MAPT 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.